

HPV AND HEAD & NECK FORUM

HPV and oropharyngeal cancer: the changing face of disease

AMSTERDAM • OCTOBER 8-9, 2017

Worldwide, HNSCC (head and neck squamous cell carcinoma) represents the sixth most common cancer. More than 15 years ago, human papillomavirus (HPV) was found to be the causative agent of a subset of head and neck cancers (HNC).

The EUROGIN HPV and Head and Neck Cancer Forum highlights areas of active investigation in this field. It offers a review of the current epidemiologic efforts which focus on the natural history of HPV infection, risk of transmission, screening for early cancer detection, and the potential impact of prophylactic HPV vaccines in the incidence of head and neck cancer. The conference evaluates how the differing biology of HPV-HNC leads to a reassessment of clinical staging and clinical prognostic characteristics. Given the viral etiology of these tumors, sessions address to review immune evasion mechanisms utilized by HPV and the understanding of these mechanisms, with the hope of opening the path to novel immunotherapeutic strategies to reactivate the host immune response against the virus and virally-associated cancer cells.

A dedicated debate session will focus on the controversies regarding the impact of HPV infection on oropharyngeal cancer, including diagnosis, management and decision making.

The relatively poor overall survival for HNSCC patients despite advances in surgical techniques, chemotherapy, and radiation therapy results has lead to significant efforts directed towards stimulating the immune response against HNSCC to improve survival and reduce morbidity.

Immunotherapy represents a promising avenue for the treatment of head and neck cancers, with several treatment regimens showing significant promise in clinical trials. Recent clinical responses observed in immunotherapy trials in HPV-OPC patients, as well as clinical results of other targeted therapies will be presented. The program will be presented by a highly ranked international scientific committee.

SCIENTIFIC COMMITTEE

L. Alemany, Spain*
M. Arbyn, Belgium
H. Berkhof, Netherlands
R. Brakenhoff, Netherlands
F. Buchinsky, USA
P. Campisi, Canada
J.D. Combes, France
A. D'Souza, USA
S. De Sanjosé, Spain
T. Dalianis, Sweden
C. Derkay, USA
C. Fakhry, USA
S. Franceschi, France
M. Gillison, USA
M. Goodman, USA
C. Götz, Germany
BH. Haughey, USA*

A. Kolk, Germany
A. Kreimer, USA
J. Lacau St. Guily, France
L. Licitra, Italy
R. Mehra, USA
K. Melief, Netherlands
H. Mirghani, France
A. Psyrri, Greece
E. Rettig, USA
R. Schlegel, USA
M. Schoenmaekers-Welters, Netherlands
S. Syrjänen, Finland
E. Tartour, France
S. Van der Burg, Netherlands
T. Waterboer, Germany



SCIENTIFIC PROGRAM

Each of these sessions is scheduled for 90 minutes and will include between 5 and 10 presentations, plus discussion. Details regarding timing and content of each session will be published here in due time. Additional sessions may be scheduled at a later stage for submitted papers.

SUNDAY, OCTOBER 8

SESSION 1

NATURAL HISTORY AND MOLECULAR BIOLOGY

CHAIR: R. BRAKENHOFF

SESSION 2

EPIDEMIOLOGY OF HPV DRIVEN HNSCC

CHAIR: M. GILLISON

SESSION 3

ORAL COMMUNICATIONS ON HPV AND HN CANCER

SESSION 4

MANAGEMENT AND DECISION MAKING IN HPV DRIVEN OROPHARYNGEAL CANCER

CHAIR: C. FAKHRY, J. LACAU ST. GUILY

SESSION 5

CONTROVERSIES ON IMPACT OF HPV INFECTION ON OROPHARYNGEAL CANCER

CHAIR: T. DALIANIS, S. SYRJÄNEN

MONDAY, OCTOBER 9

SESSION 6

UPDATE ON IMMUNOTHERAPY TRIALS IN HNSCC

CHAIR: TBA

SESSION 7

SCREENING AND PREVENTION PRE-CANCERS VS. CANCER

CHAIR: A. KREIMER

SESSION 8

THE ROLE OF EARLY ANTIGEN HPV SEROLOGY IN HEAD AND NECK CANCER

CHAIR: T. WATERBOER

SESSION 9

RECURRENT RESPIRATORY PAPILLOMATOSIS (RRP): THE CHANGING LANDSCAPE FOR PREVENTION AND TREATMENT

CHAIR: C. DERKAY

SESSION 10

ORAL COMMUNICATIONS ON HPV AND HN CANCER

CME (CONTINUING MEDICAL EDUCATION)

EUROGIN 2017 has been submitted for CME accreditation by the European Accreditation Council for Continuing Medical Education (EACCME)

SUBMIT YOUR ABSTRACT NOW! • SUBMISSION DEADLINE: APRIL 30, 2017

REGISTER BEFORE APRIL 3, 2017 AT THE EARLY REGISTRATION RATE!

For further information, including the detailed program and registration, please visit the conference website:

WWW.EUROGIN.COM/2017

CONTACT:

Peter MATTONET (Conference Manager):
Ph: +33-148 88 96 24 - peter.mattonet@eurogin.com

Claire VIEUJOT (Scientific Secretariat):
Ph: +33-144 40 01 20 - admin@eurogin.com